Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT03537742

Cardiac Allograft Vasculopathy Inhibition With Alirocumab

Conditions: Vasculopathy

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 114

Sponsor: Stanford University

Location: Stanford University Stanford California

Summary

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

Eligibility Criteria

Inclusion Criteria: * Heart Transplant recipient Exclusion Criteria: * impaired liver function

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03537742). StuddyBuddy aggregates publicly available trial information.